| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 22018 |
| Drug | Cabozantinib/Nivolumab |
| Brand | Cabometyx®/Opdivo® |
| Indication | First-line treatment of advanced renal cell carcinoma in adults. |
| Assessment Process | |
| Rapid review commissioned | 28/03/2022 |
| Rapid review completed | 11/05/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of cabozantinib (Cabometyx®) in combination with nivolumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
| Full pharmacoeconomic assessment commissioned by HSE | 27/05/2022 |
| Pre-submission consultation with Applicant | 13/08/2024 |
| Full submission received from Applicant | 12/12/2024 |
| Preliminary review sent to Applicant | 05/06/2025 |
| NCPE assessment re-commenced | 07/07/2025 |
| Factual accuracy sent to Applicant | 18/08/2025 |
| NCPE assessment re-commenced | 26/08/2025 |
| NCPE assessment completed | 19/09/2025 |
| NCPE assessment outcome | The NCPE recommends that cabo+nivo not be considered for reimbursement*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.